esuberaprost

Report
17 Pages
October 2018
Region: Global
Citeline
ID: 4775226

Drug Overview
Esuberaprost (United Therapeutics) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor.

Analyst Outlook
United Therapeutics has ceded a large advantage in the time required to develop and formulate esuberaprost as an oral prostacyclin. The pulmonary hypertension (PH) market now contains both Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) and Orenitram (treprostinil; United Therapeutics) to occupy the oral prostacyclin niche, leaving esuberaprost a much narrower potential indication to be used as an adjunctive to inhaled Tyvaso (treprostinil; United Therapeutics/Mochida). This narrow therapeutic role, combined with questions surrounding esuberaprost’s efficacy, leaves the drug with restricted commercial potential

OVERVIEW

Drug Overview
Product Profiles
esuberaprost : Pulmonary hypertension

LIST OF FIGURES

Figure 1: Esuberaprost for pulmonary hypertension – SWOT analysis
Figure 2: The authors drug assessment summary of esuberaprost for pulmonary hypertension
Figure 3: The authors drug assessment summary of esuberaprost for pulmonary hypertension
Figure 4: Esuberaprost sales for pulmonary hypertension in the US, 2016–25

LIST OF TABLES

Table 1: Esuberaprost drug profile
Table 2: Esuberaprost Phase II data in pulmonary arterial hypertension
Table 3: Esuberaprost Phase III trials in pulmonary arterial hypertension
Table 4: Esuberaprost sales for pulmonary hypertension in the US ($m), 2016–25

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9595EUR$10,000USD£8,297GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47015EUR$49,000USD£40,655GBP

Table of Contents

Related Topics

Related Reports

Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034

Pulmonary Arterial Hypertension Global Market Report 2024

Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028

Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Global Pulmonary Arterial Hypertension Drugs Market Report by Drug Class, Route of Administration, End User, and Region 2024-2032